Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06412562 in healthy male volunteers selected by cognitive phenotype
NCT02306876Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Jan 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of razpipadon in schizophrenia and cognitive impairment (3 arms), sponsored by Pfizer. Primary endpoint: Columbia Suicide Severity Rating Scale. Started Jan 2015; status: terminated.
02
Drugs
razpipadon
03
Conditions
schizophreniacognitive impairment
Beyond the preview
Go deeper on NCT02306876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02306876.